Jarrett Jennifer — SEC Form 4 filings
SEC reporting owner CIK 1671311. 22 Form 4 filings on record with FilingPulse; latest filed 2026-06-22.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2024-01-25 to 2026-06-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 10 legs across 6 filings — 205,416 shares, $3,792,975 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 26.
- Largest priced transaction: sale of 50,291 shares @ $18.97 ($954,066) in Arcus Biosciences, Inc., filed 2025-11-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | Chief Operating Officer | 12 | — | 10 legs · 205,416 sh · $3,792,975 | 15 |
| Sagimet Biosciences Inc. (SGMT) | Director | 3 | — | — | 3 |
| Syndax Pharmaceuticals Inc (SNDX) | Director | 3 | — | — | 3 |
| Zura Bio Ltd (ZURA) | Director | 3 | — | — | 3 |
| Damora Therapeutics, Inc. (DMRA) | See Remarks, Director | 1 | — | — | 2 |
Form 4 filings — Jarrett Jennifer
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-22 | 4 | Zura Bio Ltd (ZURA) | Grant/award (A): 51,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Sagimet Biosciences Inc. (SGMT) | Grant/award (A): 39,567 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Damora Therapeutics, Inc. (DMRA) | Grant/award (A): 500,000 @ $0 · Grant/award (A): 1,500,000 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Grant/award (A): 24,000 @ $0 | EDGAR |
| 2026-01-26 | 4 | Arcus Biosciences, Inc. (RCUS) | Grant/award (A): 31,000 @ $0 · Grant/award (A): 126,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Arcus Biosciences, Inc. (RCUS) | Sale (S): 11,225 @ $21.88 · Sale (S): 9,983 @ $22.16 | EDGAR |
| 2025-11-12 | 4 | Arcus Biosciences, Inc. (RCUS) | Option exercise (M): 50,291 @ $1.23 · Sale (S): 50,291 @ $18.97 · Option exercise (M): 50,291 (derivative) @ $1.23 | EDGAR |
| 2025-10-08 | 4 | Arcus Biosciences, Inc. (RCUS) | Option exercise (M): 12,500 @ $1.23 · Sale (S): 12,500 @ $14.54 · Option exercise (M): 37,792 @ $1.23 · Sale (S): 37,792 @ $15.05 · Option exercise (M): 12,500 (derivative) @ $0 · Option exercise (M): 37,792 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Sagimet Biosciences Inc. (SGMT) | Grant/award (A): 27,268 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Zura Bio Ltd (ZURA) | Grant/award (A): 51,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Grant/award (A): 25,000 @ $0 | EDGAR |
| 2025-01-27 | 4 | Arcus Biosciences, Inc. (RCUS) | Grant/award (A): 50,000 @ $0 · Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-12-17 | 4 | Arcus Biosciences, Inc. (RCUS) | Tax withholding (F): 27,501 @ $16.08 | EDGAR |
| 2024-12-11 | 4 | Zura Bio Ltd (ZURA) | Grant/award (A): 117,000 (derivative) @ $0 | EDGAR |
| 2024-09-17 | 4 | Arcus Biosciences, Inc. (RCUS) | Tax withholding (F): 12,670 @ $17.95 | EDGAR |
| 2024-08-05 | 4 | Sagimet Biosciences Inc. (SGMT) | Grant/award (A): 113,895 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Arcus Biosciences, Inc. (RCUS) | Tax withholding (F): 12,670 @ $16.97 | EDGAR |
| 2024-03-29 | 4 | Arcus Biosciences, Inc. (RCUS) | Sale (S): 11,551 @ $17.55 | EDGAR |
| 2024-03-20 | 4 | Arcus Biosciences, Inc. (RCUS) | Sale (S): 12,153 @ $17.84 · Sale (S): 1,296 @ $18.62 | EDGAR |
| 2024-02-28 | 4 | Arcus Biosciences, Inc. (RCUS) | Sale (S): 24,555 @ $20.07 · Sale (S): 34,070 @ $20.11 | EDGAR |
| 2024-02-09 | 4 | Syndax Pharmaceuticals Inc (SNDX) | Grant/award (A): 17,000 @ $0 | EDGAR |
| 2024-01-25 | 4 | Arcus Biosciences, Inc. (RCUS) | Grant/award (A): 40,000 @ $0 · Grant/award (A): 162,400 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1671311 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →